Traditional drug discovery programs target a tiny portion of proteins and often end in failure. By exploring the unexplored and drugging the undrugged, we will impact patient health.
Learn more about our science and how we’re opening new frontiers in drug discovery.
We have built the only generalizable platform across the entire proteome, expanding our target space for low-data targets, including AlphaFold2 structures, PPIs, and mutant oncogenic targets. Learn more →
Our AI-augmented, proteome-wide drug discovery platform goes from target identification to development candidate in a highly scalable and repeatable process. About our approach →
We have brought together a diverse and experienced team of biologists, chemists, computer scientists, and business professionals who are collectively passionate about changing the drug discovery paradigm. Meet our team →
By exploring the unexplored, and drugging the undrugged, Cyclica strives to impact patient health like never before. Learn more about how we collaborate with early stage biotechs and large tier one pharma alike.